SPENGA member offer · $50 off with code SPENGA50
SPENGA Powered by Apex Meds Get started
Recovery & repair · Injectable

BPC-157

Body Protection Compound-157

One peptide, one job: support the repair you train for.

BPC-157 prescribed on its own, for members who want a single, readable starting point. Evaluated by a licensed Apex MD provider and filled by a licensed U.S. pharmacy.

$249per month · injectable

SPENGA members: $50 off with code SPENGA50

  • Physician prescribed
  • Licensed U.S. pharmacy
  • Ongoing medical support
  • Arrives reconstituted
Apex Meds BPC-157 vial in SPENGA green
Form
Subcutaneous injection
Course
A set cycle, then a break
Prescribed by
Licensed Apex MD provider
Length
15 amino acids
What it is

BPC-157, in plain terms

BPC stands for Body Protection Compound. BPC-157 is a synthetic peptide of 15 amino acids, modelled on a fragment of a protective protein first described in human gastric juice in 1993.

It is not a component of any approved drug. It is prescribed as a compounded medication after a provider reviews your history.

How it works

What it does in the body

In laboratory work, BPC-157 increased the activity of a receptor on blood-vessel cells (VEGFR2) that drives nitric oxide production and new capillary growth. In tendon cells it switched on a pathway that governs how cells spread and migrate.

These findings come from cell and animal studies. The FDA's own review notes that the peptide's exact molecular target has not been identified.

The evidence

What the research shows, and what it doesn’t

Every finding is labelled by the kind of study it came from, with the source linked.

Animal and lab

A 2025 systematic review of BPC-157 in sports medicine found 36 studies. Thirty-five were animal or lab studies, which showed improved healing of muscle, tendon, ligament and bone.

Vasireddi et al., systematic review, 2025
Animal and lab

Tendon cells exposed to BPC-157 grew out, survived stress and migrated faster, through the FAK-paxillin pathway.

Chang et al., J Appl Physiol, 2011
Animal and lab

BPC-157 improved the recovery of blood flow in rats with restricted circulation to a hind limb, tied to activation of VEGFR2.

Hsieh et al., J Mol Med, 2017
Early human data

In a small retrospective series of knee-pain patients given BPC-157 by injection into the joint, most reported improvement. There was no control group.

Lee & Padgett, 2021
Not yet studied

Human research is limited to a few small, uncontrolled pilot studies. The FDA found no human study using subcutaneous injection.

FDA evaluation of BPC-157, 2026

Published research describes what was observed in a study. It is not a promise of what any product will do for you. Your provider will talk through what is realistic.

What to expect

On the protocol

01

How it's taken

A small injection just under the skin over a set cycle, followed by a break. Your provider sets the dose, the schedule and the length of the cycle. It arrives already reconstituted by the pharmacy, so there is no powder to mix and nothing to measure out.

02

What people report

Patients commonly describe first changes in pain or mobility within a few weeks. These are patient reports, not trial outcomes, and results are not guaranteed.

03

Keep your care team

Peptides are not a substitute for diagnosis, physical therapy or orthopaedic care. Tell your provider about any injury you are treating.

Safety

Know this before you start

Your provider reviews your full history. Tell them about every medication and condition, including any history of cancer.

Reported side effects

  • Redness or swelling at the injection site
  • Mild nausea
  • Headache or fatigue
  • Long-term safety has not been studied

Who should not use it

  • Active cancer or a recent history of cancer
  • Pregnancy or breastfeeding
  • Anyone under 18
  • Athletes subject to drug testing
Tested athletes

Not for drug-tested athletes

BPC-157 is prohibited at all times under the World Anti-Doping Agency's rules for non-approved substances. It is also prohibited by the NCAA and the U.S. Department of Defense.

FAQ

BPC-157 questions, answered

Is BPC-157 FDA-approved?

No. It is not approved for any condition. When prescribed it is a compounded medication, which has not been reviewed by the FDA for safety, effectiveness or quality.

Is there human research?

Very little. A few small, uncontrolled pilot studies exist. Most of the evidence comes from animal and cell studies.

How is it taken?

Typically as a small subcutaneous injection over several weeks, under your provider's direction.

How soon will I notice anything?

Patients commonly describe a few weeks, but that comes from patient reports rather than controlled trials. Results are not guaranteed.

What are the risks?

Injection-site reactions are the most common. Long-term safety has not been studied. People with cancer, or who are pregnant, should not use it.

Can I use it if I compete in tested sports?

No. It is banned in and out of competition.

Keep looking

Other peptides for SPENGA members

Exclusive SPENGA member access

Start with BPC-157

Answer a few questions. A licensed Apex MD provider decides whether it is right for you.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Prescription products require an online evaluation with a licensed medical professional, who will determine whether a prescription is appropriate. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. Research cited on this site describes published studies and is not a claim about what any product will do for you. Individual results vary.

Sources
  1. Vasireddi et al., systematic review, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
  2. Chang et al., J Appl Physiol, 2011. https://pubmed.ncbi.nlm.nih.gov/21030672/
  3. Hsieh et al., J Mol Med, 2017. https://link.springer.com/article/10.1007/s00109-016-1488-y
  4. Lee & Padgett, 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
  5. FDA evaluation of BPC-157, 2026. https://www.fda.gov/media/193343/download